Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Minot Light Capital Partners Tom Wetherald and Eddie Reilly | “The second biggest detractor in our portfolio this quarter was Lucid Diagnostics. Lucid currently markets an FDA-approved DNA test for the early detection of esophageal precancer and cancer, known as EsoGuard. We believe EsoGuard has a legitimate multi-billion dollar plus market opportunity due to its unique capabilities, outstanding clinical data and attractiveness as a minimally invasive test for nonendoscopic precancer testing. The patient need for this test is large, the company's clinical data is strong, and it has a unique position in the marketplace. The only thing holding back accelerating adoption has been a lack of reimbursement. Though we have been aware of Lucid and EsoGuard's potential for some time, we wanted further validation on the part of clinicians before taking on the risk of owning this stock in front of an upcoming rather binary Medicare approval decision. Fortunately, we were able to listen to a publicly held conference call with a Medicare Contractor Advisory Committee that took place in early September. It included an extensive discussion by several independent experts and physicians that have expertise in esophageal cancer and have analyzed EsoGuard's clinical data. The universal sentiment from this independent panel was very positive towards the test and its ability to save lives. We walked away from that call convinced that the product had strong clinical utility and had a good probability of receiving Medicare reimbursement in the next few quarters, which would then hopefully pave the way for broader commercial reimbursement and meaningful revenues for Lucid. Aside from some uncertainty around the clinical utility of EsoGuard prior to the CAC meeting of medical experts, the other reason we did not own the stock before this clinical validation was concern about the company doing multiple dilutive stock offerings in recent months, as well as the unusual corporate structure of the company and its relationship with “sister company” PavMed (PAVM). Despite these ongoing concerns, we chose to buy the stock following the CAC call, as we think EsoGuard could be worth well over $1B and the company's fully-diluted market cap was under $250M. Even if some value leaks to PavMed and assuming we were diluted again to ensure ample liquidity for the company, there is substantial potential upside in the stock and we believe the potential value of this product is truly underappreciated by the market. The reason shares of Lucid are one of our main detractors this past quarter is that days after this very positive call, the company did yet another stock offering at a meaningful discount to market, though the stock has subsequently recovered some of those losses this quarter. As we have said before, in the world of micro-cap, it is not unusual to encounter difficult decisions around companies that have been diluters and where there are concerns around corporate governance. In general, we try to avoid these situations. However, in this case, we were willing to compromise, as there is potentially huge value in EsoGuard and this has been independently verified by a large sample of independent experts. Furthermore, most serial diluters with sub-optimal corporate structures have no real product, they are simply stock promoters. In this highly unusual case, we do believe there is real value in Lucid Diagnostics, even with some future leakage. Furthermore, though we find the relationship with PavMed unusual, to their credit, the company has been very open and transparent with all disclosures around that relationship and its implications for the common stock shareholders of both companies. The realization of value from this investment will hopefully come if/when Lucid receives Medicare reimbursement for EsoGuard. Much like Torrid, when reviewing this loss from a process not outcome perspective, we would have made this investment again, but the position size should have been smaller to account for the risk of future dilution on such positive news, as well as the binary risk around Medicare reimbursement. BSD Analysis: Lucid's early-detection esophageal cancer platform has strong clinical logic, but commercialization has been slow and capital-intensive. Reimbursement momentum is improving, which could unlock adoption in a meaningful way. The technology is differentiated, yet the market doubts the company's ability to scale. Cash burn is high and patience is limited — understandable for a small-cap diagnostics story. But if uptake begins to accelerate, LUCD's TAM is substantial. This is a binary med-tech catalyst story. High risk, real upside.” | BULL | Q3 2025 Oct 1, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
